MARKET

GNCA

GNCA

Genocea
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.470
-0.090
-3.52%
After Hours: 2.480 +0.01 +0.40% 17:50 10/20 EDT
OPEN
2.560
PREV CLOSE
2.560
HIGH
2.640
LOW
2.290
VOLUME
656.82K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
1.100
MARKET CAP
74.01M
P/E (TTM)
-1.6854
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Genocea Biosciences (GNCA) Stock Outpacing Its Medical Peers This Year?
Is (GNCA) Outperforming Other Medical Stocks This Year?
Zacks · 5d ago
Genocea Announces Upcoming Data Presentations at Virtual SITC 2020
Will showcase clinical and immune responses from the ongoing GEN-009 Phase 1/2a trial Will provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the limitations of TIL and TCR therapiesWill share new insights on the utility of InhibigensTM as identified by ATLASTM to inform immunotherapy development CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the titles and times of its presentations at the upcoming 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9th – 14th.The following posters will be available on Monday, November 9 at 8 a.m. ET:Abstract Number: 390 Title: Emerging safety and activity data from GEN-009-101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 checkpoint inhibitors (CPI) in advanced solid tumorsAbstract Number: 413 Title: GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumorsAbstract Number: 149 Title: GEN-011: An ATLAS™-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approachesAbstract Number: 526 Title: InhibigenTM-specific responses suppress anti-tumor immunity and promote tumor growthPer SITC policy, full abstracts are embargoed until 8 a.m. ET on November 9, 2020.About Genocea Biosciences, Inc. Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit www.genocea.com.Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.Investor Contact: Dan Ferry 617-430-7576 daniel@lifesciadvisors.com
GlobeNewswire · 6d ago
Genocea to Initiate a Phase I/II Oncology Study on GEN-011
Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.
Zacks · 09/23 16:40
Genocea Up 5% On FDA Nod For Cancer Therapy Application; Street Sees 353% Upside
Genocea Biosciences announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its GEN-011 cancer immunotherapy, sending shares up 5% in Tuesday’s pre-market session.Genocea (GNCA), which is developing next-generation neoantigen immunotherapies
SmarterAnalyst · 09/22 14:05
GME, CVNA among premarket gainers
AIM ImmunoTech (AIM) +25% on receiving significant positive survival results in pancreatic cancer from Erasmus University Medical Center.GameStop (GME) +18% after RC Ventures discloses stake.Rockwell Medical (RMTI) +13%.Cassava Sciences (SAVA) +13% on insider buying.Carvana (CVNA) +13% as
Seekingalpha · 09/22 12:24
Genocea on go with early-stage study of cancer candidate GEN-011
Genocea Biosciences' (GNCA) +11% in premarket in reaction to the FDA acceptance of investigational new drug application ((IND)) for GEN-011, an adoptive T cell therapy targeting neoantigens.The IND allows to commence a Phase 1/2a
Seekingalpha · 09/22 11:49
FDA accepts Genocea' application to initiate early-stage study for GEN-011 in cancer
Genocea Biosciences' (GNCA) +11% in premarket in reaction to the FDA acceptance of investigational new drug application ((IND)) for GEN-011, an adoptive T cell therapy targeting neoantigens.The IND allows to commence a Phase 1/2a
Seekingalpha · 09/22 11:49
Genocea Biosciences announces follow-up data from GEN-009 Neoantigen Vaccine phase 1/2a trial
Genocea Biosciences (GNCA) +11% announces follow up data from the first five patients vaccinated in Part B of the ongoing GEN-009 Phase 1/2a trial at the European Society for Medical Oncology Virtual
Seekingalpha · 09/17 09:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNCA. Analyze the recent business situations of Genocea through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNCA stock price target is 9.40 with a high estimate of 18.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 14.37M
% Owned: 47.96%
Shares Outstanding: 29.96M
TypeInstitutionsShares
Increased
13
331.21K
New
7
31.44K
Decreased
9
716.37K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.90%
Pharmaceuticals & Medical Research
-0.28%
Key Executives
Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
William Clark
Chief Financial Officer
Diantha Duvall
Senior Vice President
Narinderjeet Singh
Chief Scientific Officer
Jessica Flechtner
Senior Vice President
Narinder Singh
Other
Girish Aakalu
Other
Thomas Davis
Director
Gisela Schwab
Independent Director
Ali Behbahani
Independent Director
Katrine Bosley
Independent Director
Ronald Cooper
Independent Director
Michael Higgins
Independent Director
George Siber
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GNCA
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009 program, which is a neoantigen vaccine candidate. The Company is conducting a Phase 1/2a clinical trial across a range of solid tumor types. It also provides GEN-011, which is a neoantigen-specific adoptive T cell therapy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Genocea Biosciences Inc stock information, including NASDAQ:GNCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNCA stock methods without spending real money on the virtual paper trading platform.